GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thor Medical ASA (LTS:0R6Y) » Definitions » EV-to-EBITDA

Thor Medical ASA (LTS:0R6Y) EV-to-EBITDA : -15.54 (As of May. 31, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Thor Medical ASA EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Thor Medical ASA's enterprise value is kr623.07 Mil. Thor Medical ASA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was kr-40.10 Mil. Therefore, Thor Medical ASA's EV-to-EBITDA for today is -15.54.

The historical rank and industry rank for Thor Medical ASA's EV-to-EBITDA or its related term are showing as below:

LTS:0R6Y' s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.02   Med: -1.03   Max: 2.29
Current: -15.53

During the past 13 years, the highest EV-to-EBITDA of Thor Medical ASA was 2.29. The lowest was -21.02. And the median was -1.03.

LTS:0R6Y's EV-to-EBITDA is ranked worse than
100% of 497 companies
in the Biotechnology industry
Industry Median: 8.25 vs LTS:0R6Y: -15.53

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-31), Thor Medical ASA's stock price is kr2.41. Thor Medical ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was kr-0.179. Therefore, Thor Medical ASA's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Thor Medical ASA EV-to-EBITDA Historical Data

The historical data trend for Thor Medical ASA's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thor Medical ASA EV-to-EBITDA Chart

Thor Medical ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.39 -4.64 3.56 -53.68 -15.33

Thor Medical ASA Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.56 - -53.68 - -15.33

Competitive Comparison of Thor Medical ASA's EV-to-EBITDA

For the Biotechnology subindustry, Thor Medical ASA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thor Medical ASA's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thor Medical ASA's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Thor Medical ASA's EV-to-EBITDA falls into.


;
;

Thor Medical ASA EV-to-EBITDA Calculation

Thor Medical ASA's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=623.066/-40.1
=-15.54

Thor Medical ASA's current Enterprise Value is kr623.07 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Thor Medical ASA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was kr-40.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Thor Medical ASA  (LTS:0R6Y) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Thor Medical ASA's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.41/-0.179
=At Loss

Thor Medical ASA's share price for today is kr2.41.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Thor Medical ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was kr-0.179.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Thor Medical ASA EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Thor Medical ASA's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Thor Medical ASA Business Description

Traded in Other Exchanges
Address
Karenslyst Alle 9C, Oslo, NOR, 0278
Thor Medical ASA is a Norway-based biopharmaceutical company. The Company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. The Company has developed a proprietary technology for the manufacturing of radionuclides, alpha-particle emitters from natural resources. The high energy deposition and the short range of alpha particles make it possible to eradicate cancer cells while minimizing damage to nearby healthy cells.

Thor Medical ASA Headlines

No Headlines